The discovery of anti–NMDA receptor encephalitis in 2007 provided enormous boosts
to immunological research in neurology and psychiatry. Anti–NMDA receptor encephalitis
is associated with severe neurological and a plethora of psychiatric symptoms, including
psychotic and affective phenomena (
1
,
2
). To date, several more well-characterized neuronal autoantibodies have been described
(
1
,
2
). According to current international consensus criteria, a diagnosis of possible
autoimmune encephalitis (AE) should be considered in the presence of a subacute neuropsychiatric
syndrome (with severe working memory deficits, an altered mental state, or psychiatric
symptoms) in combination with at least one further organic sign, such as inflammatory
cerebrospinal fluid (CSF) changes with an increased white blood cell (WBC) count,
suspicious magnetic resonance imaging (MRI) changes, epileptic seizures, or focal
neurological signs (
2
).
SEE CORRESPONDING ARTICLE ON PAGE 563
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Autoantibodies in neurological disease.Nat Rev Immunol. 2021; 21: 798-813
- A clinical approach to diagnosis of autoimmune encephalitis.Lancet Neurol. 2016; 15: 391-404
- Autoimmune psychosis: An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin.Lancet Psychiatry. 2020; 7: 93-108
- Clinical manifestations and immunomodulatory treatment experiences in psychiatric patients with suspected autoimmune encephalitis: A case series of 91 patients from Germany.Mol Psychiatry. 2022; 27: 1479-1489
- Spectrum of novel anti–central nervous system autoantibodies in the cerebrospinal fluid of 119 patients with schizophreniform and affective disorders.Biol Psychiatry. 2022; 92: 261-274
- Cerebrospinal fluid analysis: Disease-related data patterns and evaluation programs.J Neurol Sci. 2001; 184: 101-122
- Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis.Transl Psychiatry. 2020; 10: 279
- Neuroinflammatory biomarkers in cerebrospinal fluid from 106 patients with recent-onset depression compared with 106 individually matched healthy control subjects.Biol Psychiatry. 2022; 92: 563-572
- Cerebrospinal fluid biomarkers in patients with unipolar depression compared with healthy control individuals: A systematic review and meta-analysis.JAMA Psychiatry. 2022; 79: 571-581
- Neuroimmunological investigations of cerebrospinal fluid in patients with recent onset depression - A study protocol.BMC Psychiatry. 2022; 22: 35
Article info
Publication history
Accepted:
June 27,
2022
Received:
June 26,
2022
Identification
Copyright
© 2022 Society of Biological Psychiatry.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Neuroinflammatory Biomarkers in Cerebrospinal Fluid From 106 Patients With Recent-Onset Depression Compared With 106 Individually Matched Healthy Control SubjectsBiological PsychiatryVol. 92Issue 7Open Access
